Pyxis Oncology (PYXS) closed at $1.44 on November 17, 2026, up 2.1% from the previous close, on volume of 1,409,725 shares (30-day average 806,821).
Data as of November 17, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 17, 2026. See the largest for 5, 30, 60 and 90 days
Pyxis Oncology Stockholders Approve Authorized Share Increase
TipRanks (Fri, 13-Nov 4:57 PM ET)
Globe Newswire (Thu, 5-Nov 7:00 AM ET)
Pyxis Oncology to Participate in Upcoming Investor Conferences
Globe Newswire (Wed, 28-Oct 7:30 AM ET)
Globe Newswire (Tue, 27-Oct 8:45 AM ET)
Pyxis Oncology Announces Closing of Up to $282.6 Million Public Offering
Globe Newswire (Fri, 2-Oct 7:00 AM ET)
Pyxis Oncology Announces Pricing of Up to $282.6 Million Public Offering
Globe Newswire (Wed, 30-Sep 1:11 AM ET)
Pyxis Oncology Announces Proposed Public Offering
Globe Newswire (Tue, 29-Sep 4:24 PM ET)
Globe Newswire (Wed, 9-Sep 7:00 AM ET)
Globe Newswire (Tue, 8-Sep 4:01 PM ET)
Pyxis Oncology Appoints Thomas Civik Chief Executive Officer and Chairman of the Board
Globe Newswire (Tue, 8-Sep 7:30 AM ET)
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.
Pyxis Oncology trades on the NASDAQ stock market under the symbol PYXS.
As of November 18, 2026, PYXS stock price declined to $1.42 with 25,575 million shares trading.
PYXS has a beta of 2.41, meaning it tends to be more sensitive to market movements. PYXS has a correlation of 0.03 to the broad based SPY ETF.
PYXS has a market cap of $169.84 million. This is considered a Micro Cap stock.
In the last 3 years, PYXS traded as high as $6.85 and as low as $.83.
The top ETF exchange traded funds that PYXS belongs to (by Net Assets): VTI, VXF, IBB, IWC, BUSM.
PYXS has underperformed the market in the last year with a price return of -69.5% while the SPY ETF gained +10.9%. PYXS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -53.0% and -13.4%, respectively, while the SPY returned -5.2% and -3.2%, respectively.
PYXS support price is $1.36 and resistance is $1.52 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PYXS shares will trade within this expected range on the day.